Biohaven BHVN Business Segments — Direct R&D program expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept bhvn:ResearchAndDevelopmentProgramExpense.
The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biohaven's business segments — direct r&d program expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biohaven's business segments — direct R&D program expense?
- Biohaven (BHVN) reported business segments — direct R&D program expense of $19.73M in Q1 2026.
- How has Biohaven's business segments — direct R&D program expense changed year-over-year?
- Biohaven's business segments — direct R&D program expense decreased by 37.5% year-over-year, from $31.57M to $19.73M.
- What is the long-term trend for Biohaven's business segments — direct R&D program expense?
- Over 3 years (2022 to 2025), Biohaven's business segments — direct R&D program expense has grown at a -4.4% compound annual growth rate (CAGR), from $131.96M to $115.27M.
- What does business segments — direct R&D program expense mean?
- Represents the direct costs associated with specific clinical-stage research and development programs within the reportable business segment. This metric captures the capital allocated to advancing therapeutic candidates through the clinical trial pipeline. Monitoring this helps investors assess the company's commitment to its core drug development initiatives.